News

The new facilities consist of instrumentation, organic and analytical chemistry laboratories, office space for newly created scientific positions, conference rooms and employee common areas. Triclinic is set to

Jointly developed by Affymax and Takeda, peginesatide is a synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an erythropoiesis stimulating

AMR101 is a prescription-grade omega-3 fatty acid indicated for the treatment of patients with very high triglyceride levels (>500 mg/dL) and as a potentially first-in-class therapy for patients

The remaining minority share of Ubichem Research remains in the ownership of Jozsef Repasi, managing director of Ubichem Research. Following the acquisition, Ubichem Pharma Services will continue to

Under the agreement, Heptares will make use of its GPCR discovery expertise including StaR technology with Astrazeneca’s biopharmaceutical discovery, development and commercial capabilities. The tie up aims at

Greciet will succeed Dominique Costantini, co-foundator and CEO of BioAlliance Pharma. She is working as the chief operating officer of the company since 1 March 2011. Greciet has

The milestone triggers from the initiation of a Phase I clinical trial of an experimental compound by Boehringer Ingelheim for the treatment neuropathic pain. Previously, Evotec had entered

Lixisenatide, a glucagon-like peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus. The study showed reduction in HbA1c versus placebo for

Nimotuzumab, a humanized monoclonal antibody targeting EGFR, is indicated for the patients with brain metastasis from non-small cell lung cancer (NSCLC) and palliative treatment of NSCLC. YM BioSciences